Dr. Lal Path Labs to acquire 70% stake in SN Genelab for up to ₹168 Cr
Dr. Lal Path Labs will acquire 70% of SN Genelab for up to ₹168 Crores plus a ₹31.5 Crores earn-out. The acquisition aims to enhance genomics expertise and diagnostic services. SN Gene's FY26 turnover was ₹57.96 Crores. The deal is expected to close by November 30, 2026.
The acquisition involves a significant cash consideration and expands the company's service offerings into a specialized area (genomics), which could have a medium-term impact on its market position and financial performance. The amount is material but not transformative.
The acquisition of SN Genelab is expected to strengthen Dr. Lal Path Labs' capabilities in the genomics sector and expand its service portfolio, which is a positive development for the company's growth.
Dr. Lal Path Labs Limited announced on September 24, 2026, that its Board of Directors has approved the acquisition of a 70% stake in SN Genelab Private Limited ("SN Gene") from its existing shareholders. Following this acquisition, SN Gene will become a subsidiary of Dr. Lal Path Labs.
The acquisition is aimed at strengthening the company's expertise in genomics and broadening its portfolio of advanced diagnostic services. SN Gene, incorporated in 2013 in Gujarat, operates in the diagnostics - genomics sector.
The total consideration for the acquisition is up to ₹168 Crores in cash, with an additional performance-linked earn-out capped at ₹31.5 Crores. For FY2026, SN Gene reported a turnover of ₹57.96 Crores, with turnovers of ₹53.36 Crores in FY2025 and ₹43.27 Crores in FY2024.
The transaction is not considered a related party transaction. The indicative time period for the completion of the acquisition is by November 30, 2026. The Board Meeting commenced at 04:40 P.M. (IST) and concluded at 05:11 P.M. (IST).
What to do with a filing like this
Dr. Lal Path Labs Ltd. filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Lal Path Labs Ltd.. Read the original for the full detail.